学科主题基础医学
Design, Synthesis and Biological Activities of a Series of Piperazine Pyrimidine as CCR4 Antagonists
Gong Hong-Wei1,2,3; Qi Hui4; Sun Wei1; Jiang Dan3; Xia Jun-Hai3; Yang Xiao-Hong1; Wang Ying4; Li Song3
关键词CCR4 antagonists Chemokine-like factor 1 (CKLF1) Thymus and activation regulated chemokine (TARC) Macrophage-derived chemokine (MDC) Inflammatory disease
刊名CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
2013-09-10
DOI10.7503/cjcu20120607
34期:9页:2131-2138
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Chemistry, Multidisciplinary
研究领域[WOS]Chemistry
关键词[WOS]AIRWAY INFLAMMATION ; CHEMOKINE ; POTENT ; OPTIMIZATION ; HYPERRESPONSIVENESS ; ASTHMA ; THYMUS ; CELLS ; MICE
英文摘要

CC chemokine receptor 4( CCR4) is a pivotal factor in the development of allergic inflammations, such as asthma, dermatitis and rhinitis. CCR4 antagonists have a huge potential in the therapeutics of the allergic diseases, and BMS-397 is the most potent CCR4 antagonists in the reported compounds. The structure-activity relationship of BMS-397 was studied and the large influence of the groups of pyridine and piperidine on the activity led us to modify these two sites. A series of piperazine pyrimidine derivatives was designed and synthesized. Their structures were characterized by H-1 NMR, C-13 NMR, MS and elemental analysis. The activities of all the newly synthesized compounds were evaluated using a chemotaxis inhibition assay. The results of biological activity experiment show that compound 8a was more potent than BMS-397. In the murine rhinitis model, budesonide was used as the calibration or comparison standard to assess the relative efficacy of compound 8a. The results show that compound 8a was more effective than budesonide, revealed excellent affinity to N-terminal of CCR4, and the apparent binding constant of CZE experiment result was (3. 6179 +/- 0. 5976) x 10(4) L/mol.

语种中文
WOS记录号WOS:000328926400019
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
版本出版稿
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56326
专题北京大学基础医学院_北京大学人类疾病基因研究中心
作者单位1.Jilin Univ, Sch Publ Hlth, Changchun 130021, Peoples R China
2.Jilin Univ, Sch Pharmaceut Sci, Changchun 130021, Peoples R China
3.Acad Mil Med Sci, Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China
4.Peking Univ, Ctr Human Dis Genom, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Gong Hong-Wei,Qi Hui,Sun Wei,et al. Design, Synthesis and Biological Activities of a Series of Piperazine Pyrimidine as CCR4 Antagonists[J]. CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE,2013,34(9):2131-2138.
APA Gong Hong-Wei.,Qi Hui.,Sun Wei.,Jiang Dan.,Xia Jun-Hai.,...&Li Song.(2013).Design, Synthesis and Biological Activities of a Series of Piperazine Pyrimidine as CCR4 Antagonists.CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE,34(9),2131-2138.
MLA Gong Hong-Wei,et al."Design, Synthesis and Biological Activities of a Series of Piperazine Pyrimidine as CCR4 Antagonists".CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE 34.9(2013):2131-2138.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
哌嗪嘧啶类CCR4拮抗剂的设计、合成及生(1281KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Gong Hong-Wei]的文章
[Qi Hui]的文章
[Sun Wei]的文章
百度学术
百度学术中相似的文章
[Gong Hong-Wei]的文章
[Qi Hui]的文章
[Sun Wei]的文章
必应学术
必应学术中相似的文章
[Gong Hong-Wei]的文章
[Qi Hui]的文章
[Sun Wei]的文章
相关权益政策
暂无数据
收藏/分享
文件名: 哌嗪嘧啶类CCR4拮抗剂的设计、合成及生物活性.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。